Swedish Orphan Biovitrum AB SOBI
OMXSTO · Sweden · Health Technology
SEK 434.40-6.00 (-1.36%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
As per 30 September 2026, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,636,514 shares. All shares are common shares. The total number of votes is 357,636,514. The increase in the number of shares and votes results from the issue of 223,677 class C shares. The class C shares were issued for the purpose of ensuring fulfilment of commitments under the long-term incentive programme for permanent employees (the All Employee Programme) and have by virtue of t
Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026), taking place 26-29 September in Rotterdam, the Netherlands.
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of +77.27% and +39.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.